Skip to main content
News

Emergent BioSolutions inks deal for smallpox newcomer Tembexa

By August 3, 2022No Comments
Emergent Logo

Emergent LogoEmergent BioSolutions, already flush with products against public health threats like anthrax attacks and opioid overdoses, is expanding its arsenal of medical countermeasures by scooping up global rights to smallpox newcomer Tembexa.

Emergent will furnish developer Chimerix with $225 million in upfront cash plus upward of $100 million in milestone payments for worldwide rights to the med, also known as brincidofovir. The drug last summer snagged FDA approval as the first antiviral cleared to treat smallpox regardless of a patient’s age.

 

{iframe}https://www.fiercepharma.com/pharma/emergent-beefs-countermeasure-repertoire-325m-deal-chimerixs-smallpox-newcomer-tembexa{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.